News

AmacaThera Partners with Pacira BioSciences on Pain Management

AmacaThera Partners with Pacira BioSciences on Pain Management

AmacaThera Forms Strategic Alliance with Pacira BioSciences

AmacaThera is thrilled to announce a groundbreaking global partnership with Pacira BioSciences, paving the way for innovative therapeutic solutions in pain management. The agreement involves an immediate payment of US$5 million, complemented by potential future milestone payments totaling up to US$225 million. This partnership primarily focuses on AMT-143, AmacaThera's pioneering long-acting non-opioid anesthetic aimed at alleviating post-operative pain.

Understanding AMT-143 and Its Innovative Platform

Tunable Hydrogel Technology

At the heart of this agreement is AmacaThera's revolutionary tunable hydrogel technology. This platform enables the precise and controlled local delivery of drugs like ropivacaine, ensuring sustained release that can last for up to 14 days. By leveraging this cutting-edge technology, AmacaThera aims to improve patient outcomes while addressing key challenges in current pain management practices.

Collaborative Clinical Development Plans

As part of the collaboration, AmacaThera and Pacira will work together to advance a Phase 2 clinical program, with Pacira funding the necessary clinical development, manufacturing, and commercialization efforts. Aiming for a program start in 2026, this collaboration is positioned to significantly enhance the prospects of AMT-143 entering the market.

Significance of the Partnership

This alliance not only validates AmacaThera's robust hydrogel platform but also positions it to expand its reach in multiple therapeutic areas. The ability to deliver drugs effectively while minimizing opioid use is particularly significant in today's healthcare landscape, where non-opioid alternatives are in high demand.

CEO Insights on the Collaboration

Expressing enthusiasm for this partnership, Mike Cooke, the CEO of AmacaThera, stated, "This collaboration with Pacira is a major validation of our tunable hydrogel platform and our approach to developing long-acting therapies. This partnership allows us to accelerate AMT-143's development while showcasing our technology's strength and versatility to potential future partners."

Key Highlights of the Licensing Agreement

  • Partnership Significance: Collaborating with a leader in pain management underscores the credibility of AmacaThera’s hydrogel innovation.
  • Funding Structure: The arrangement provides non-dilutive funding, enabling AmacaThera to maintain ownership while enhancing innovation.
  • Superior Hydrogel Technology: AmacaThera's hydrogel is designed for simpler manufacturing processes and tunable effects, distinguishing it from competitors.
  • Commercial Scalability: Established manufacturing practices ensure ease in scaling up and transferring technology to partners.
  • Revenue Potential: The structured milestones and royalties align with AmacaThera’s strategy for a diversified, scalable pipeline.

Future Prospects and Market Impact

Jonathan Slonin, MD, MBA, CMO of Pacira BioSciences, expressed excitement about adding AMT-143 to their pipeline. He stated, "This unique long-acting formulation is easy to use and has the potential to provide significant postoperative pain relief without relying on opioids, addressing a crucial need in today’s market." The collaboration is an emblem of shared vision in bringing innovative solutions to the forefront of pain management.

About AmacaThera

AmacaThera is a pioneer in developing next-generation hydrogel-based drug delivery systems. Their proprietary platform utilizes known biocompatible polymers to create a hydrogel that transforms from liquid to gel at body temperature, allowing for prolonged and target-specific drug release. This innovative approach can facilitate the effective administration of various therapeutics, enhancing both patient compliance and therapeutic efficacy.

Frequently Asked Questions

What is the purpose of the partnership between AmacaThera and Pacira BioSciences?

The partnership aims to develop AMT-143, a long-acting non-opioid anesthetic for post-operative pain management.

What is the significance of AmacaThera's hydrogel platform?

The hydrogel platform allows precise, controlled, and sustained drug delivery, improving therapeutic outcomes and addressing pain effectively.

What are the financial terms of the agreement?

AmacaThera will receive an upfront payment of US$5 million and up to US$225 million in milestone payments along with royalties on net sales.

When is the Phase 2 clinical program expected to begin?

The Phase 2 clinical program is projected to start in 2026.

What expertise does Pacira BioSciences bring to the partnership?

Pacira is recognized as a leader in non-opioid pain management, providing invaluable experience in bringing innovative therapies to market.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 126

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 35

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 196

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
COSCO Shipping Uses CIIE to Put People in the Chain

Updated Category News Views 87

A Supply Chain Is Not Just Steel and Schedules Containers do not shake hands, but the people routing them certainly do. That was the useful, rather human point underneath COSCO SHIPPING's presence at the ninth China International Import Expo in Shanghai: global logistics is a physical business built on relationships that have to survive different languages, markets,...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 39

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 115

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 97

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 74

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 48

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading

Top 5 Most Recently Viewed Articles

Business Jet Steals the Spotlight with Starlink Installation

Updated Category News Views 350

Business Jet Achieves Significant Milestone with Starlink Business Jet has proudly completed the first installation of Starlink on the Embraer Legacy 600 certification aircraft. This innovative achievement signifies a major step in enhancing the inflight connectivity experience for clients, marking the Legacy 600 as a pioneer aircraft equipped with Starlink capabilities....

Continue Reading
Understanding the Importance of Snow Removal for Roof Safety

Updated Category News Views 166

Understanding the Importance of Roof Snow Removal When it comes to maintaining the safety of your home during winter, one crucial task often overlooked is roof snow removal. Roofing expert John Kolarik from Mariage Roofing shares valuable insights on why homeowners should be proactive about this important aspect of winter maintenance. Removing snow from roofs not only...

Continue Reading
Teck Resources Plans Significant Share Buyback Initiative

Updated Category News Views 126

Teck Resources Limited's Normal Course Issuer Bid Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has exciting news as it prepares to initiate a normal course issuer bid aimed at repurchasing its Class B subordinate voting shares. With the Toronto Stock Exchange’s approval, Teck is set to purchase up to 40 million of these shares, equating to roughly 7.9% of...

Continue Reading
SR Bancorp Sees Fluctuations in Quarterly Income Performance

Updated Category News Views 192

Introduction to SR Bancorp, Inc. SR Bancorp, Inc. (NASDAQ: SRBK), the holding company for Somerset Regal Bank, has recently published its quarterly financial results, reflecting changes in net income and asset growth. In the most recent quarter, the company demonstrated resilience and adaptability amidst fluctuating market conditions. Net Income Overview Financial Results...

Continue Reading
Reddit Inc's Stock Surges: Navigating Mispricing and Strategies

Updated Category News Views 146

Reddit Inc Experiences Remarkable Stock Surge After being under pressure for much of the spring, shares of Reddit Inc (NYSE: RDDT) have rebounded dramatically. The stock experienced a surge of over 50% within a span of just two weeks, decisively breaking out of its previous trading range and reaching all-time highs. This notable rebound is striking, especially considering...

Continue Reading